Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Nicholas Crihfield v. CytRx Corporation et al
Case Number:
2:16-cv-05519
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Glancy Prongay
- Kirkland & Ellis
- Levi & Korsinsky
- Pomerantz LLP
- Robbins Geller
- Rosen Law Firm PA
- Skadden Arps
- Zimmerman Reed
Companies
Sectors & Industries:
-
May 07, 2018
CytRx Investors Seek OK On $5.75M Stock Drop Settlement
An investor suing biopharmaceutical company CytRx Corp. over alleged misstatements that hurt its share price asked a California federal court on Friday for preliminary approval of a $5.75 million settlement.
-
November 20, 2017
CytRx Investors Seek Cert. In Suit Over Cancer Drug Trial
Investors suing biopharmaceutical company CytRx Corp. for allegedly misrepresenting the success of a late-stage trial of a cancer treatment urged a California federal court Friday to certify a class of investors who purportedly suffered losses due to the company's statements.
-
July 25, 2016
CytRx Hit With Investor Suit Related To FDA Hold On Drug
CytRx Corp. was hit with a proposed securities class action Monday in California federal court by investors who say the biopharmaceutical company concealed bad news affecting the company's business arising from a U.S. Food and Drug Administration hold on its cancer trial drug, aldoxorubicin.